Source: International Congress 2014 – ILDs 3
Disease area: Interstitial lung diseases

Abstract

Objective: To evaluate the effects of Dengzhanshengmai (DZSM) capsules, traditional chinese medicin, on bleomycin-induced murine lung fibrosis.Methods: Female mice were divided into three groups averagely and randomly: saline, bleomycin and DZSM group. Pulmonary fibrosis models were generated by intratracheally instilled of bleomycin and then treated with saline and DZSM solution for 21 days respectively. The body weight was recorded every two days. After the last treatment, the lung resistance was tested using Buxco invasive lung mechanics machine. Lung tissues were collected after the mice were killed and observed following staining with H&E solution or Masson's solution to estimate the inflammatory level and fibrosis degree respectively. BALF were collected for inflammatory cytokines assay. Hydroxyproline levels were also detected to estimate fibrosis degree.Results: The body weights was significantly decreased after giving bleomycin. DZSM solution (222 mg·kg^-1·day^-1) could retard the loss of body weights and improve the lung resistance significantly (P < 0.05). The inflammatory cytokines such as TGF-b,TNF-a,IL-1b in BALF and the hydroxyproline level in lung tissue were also significantly down-regulated (P < 0.05). Furthermore, the inflammatory state and fibrosis level were also relieved in pathological specimens.Conclusions: DZSM capsules could improve the weakness in bleomycin-induced pulmonary fibrosis mouse models, lower the lung resistance, inhibit the inflammatory statement, decrease the hydroxyproline levels and inflammatory cytokines levels and relieve fibrosis.

Rating:

Share or cite this content

Citations should be made in the following way:
Y. Tan, Q. Zeng, H. Sun, D. Xiao (Guangzhou, China). Protective effects of Dengzhanshengmai capsules on bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 2014; 44: Suppl. 58, 778

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 Description of a murine model of acute pneumonitis hypersensitivity to pigeon serum Source: International Congress 2014 – ILDs 2 Year: 2014 Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Thymosin beta4 protects mice from bleomycin-induced damage in the lung Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Resveratrol regulates ECM remodeling in lung fibrosis Source: International Congress 2014 – New and old players in fibrotic lung disease Year: 2014 Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases Year: 2013 Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling Source: International Congress 2014 – ILDs 4 Year: 2014 Neurogenic pulmonary edema: Effect of corticosteroids Source: International Congress 2015 – Pathogenic mechanisms of lung transplant complications: a focus on CLAD Year: 2015 Pirfenidone and BIBF1120 regulate properties of myofibroblasts Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Aerobic training inhibits bleomycin-induced pulmonary fibrosis in BALB/c mice Source: International Congress 2014 – Animal models: asthma, COPD and beyond Year: 2014 Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions Year: 2015 Targeting the hedgehog/GLI pathway decreases bleomycin-induced lung fibrosis Source: Annual Congress 2013 –Translational studies in chronic repair and remodelling in the lung Year: 2013 Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 LATE-BREAKING ABSTRACT: The effects and mechanism of adiponectin on inhibiting pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Infliximab, an anti-tumor necrosis factor-α attenuates bleomycin-induced pulmonary fibrosis in rats Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital Source: International Congress 2014 – ILDs 4 Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014